FDA
-
-
-
-
-
-
-
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
-
-
-
-
-
-
-
Weight Watchers integrates with Eli Lilly's LillyDirect platform
-
-
-
-
-
-
-
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
-
-
-
-
-
-
-
Lilly's retatrutide shows significant weight loss in phase 3 trial
-
-
-
-
-
-
-
Eli Lilly invests additional $4.5 billion in Indiana manufacturing sites
-
-
-
-
-
-
-
Lilly surges on earnings beat and raised guidance
-
-
-
-
-
-
-
Leerink Partners now expects Eli Lilly's (LLY) Foundayo in diabetes to be approved in 2H26
-
323,981 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

